`
`______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`______________
`
`Sawai USA, Inc., Sawai Pharmaceutical Co., Ltd.,
`Petitioners,
`
`v.
`
`Nissan Chemical Industries Ltd.,
`Patent Owner
`________________
`
`U.S. Patent No. 5,856,336
`
`Issue Date: January 5, 1999
`
`Title: Quinoline Type Mevalonolactones
`
`________________
`
`Inter Partes Review No. IPR2015-01647
`
`PATENT OWNER’S MANDATORY DISCLOSURES
`UNDER 37 C.F.R. § 42.8
`
`
`
`I.
`
`37 C.F.R. § 42.8(b)(1) – NOTICE OF REAL PARTY IN INTEREST
`
`The real parties in interest are Nissan Chemical Industries, Ltd., Kowa
`
`Company, Ltd., and Kowa Pharmaceuticals America, Inc.
`
`II.
`
`37 C.F.R. § 42.8(b)(2) – RELATED MATTERS
`
`A Petition for inter partes review of U.S. Patent No. 5,856,336 (the “‘336
`
`Patent”), IPR2015-01069, was filed on April 18, 2015 by Mylan Pharmaceuticals
`
`Inc. At the time of this filing, the Board has not decided whether or not to institute
`
`review in that proceeding.
`
`The Petitioners in this proceeding also filed an additional petition for inter
`
`partes review of the same ‘336 Patent on the same date, July 31, 2015. See IPR
`
`2015-01648.
`
`Plaintiffs assert that defendants in the following litigations infringe the ‘336
`
`Patent: Kowa Company, Ltd., et. al. v. Amneal Pharmaceuticals, LLC, 1:14-cv-
`
`02758 (S.D.N.Y., April 17, 2014); Kowa Company, Ltd., et. al. v. Aurobindo
`
`Pharma Limited, et. al., 1:14-cv-02497 (S.D.N.Y., April; 9, 2014); Kowa
`
`Company, Ltd., et. al. v. Mylan, Inc., et. al., 1:14-cv-02647 (S.D.N.Y., April 14,
`
`2014); Kowa Company, Ltd., et. al. v. Orient Pharma Co., Ltd., 1:14-cv-02759
`
`(S.D.N.Y., April 17, 2014); Kowa Company, Ltd., et. al. v. Sawai USA, Inc, et. al.,
`
`1:14-cv-05575 (S.D.N.Y., July 23, 2014); and Kowa Company, Ltd., et. al. v.
`
`2
`
`
`
`Zydus Pharmaceuticals (USA) Inc., et. al., 1:14-cv-02760 (S.D.N.Y., April 17,
`
`2014).
`
`III.
`
`37 C.F.R. § 42.8(b)(3) – LEAD AND BACKUP COUNSEL
`
`Lead Counsel: David G. Conlin (Reg. No. 27,026); Tel.: 617-348-1856;
`
`Fax: 617-542-2241; Address: Mintz Levin Cohn Ferris Glovsky and Popeo, P.C.,
`
`One Financial Center, Boston, MA 02111; email: DGConlin@mintz.com.
`
`Backup Counsel: Kathleen B. Carr (Reg. No. 41,658); Tel.: 617-348-1857;
`
`Fax: 617-542-2241; Address: Mintz Levin Cohn Ferris Glovsky and Popeo, P.C.,
`
`One Financial Center, Boston, MA 02111; email: KBCarr@mintz.com; David
`
`Cotta (Reg. No. 52,771); Tel.: 617-348-1861 Fax: 617-542-2241; Address: Mintz
`
`Levin Cohn Ferris Glovsky and Popeo, P.C., One Financial Center, Boston, MA
`
`02111; email: DCotta@mintz.com; Peter J. Cuomo (Reg. No. 58,481); Tel.:617-
`
`348-1854; Address: Mintz Levin Cohn Ferris Glovsky and Popeo, P.C., One
`
`Financial Center, Boston, MA 02111; email: PJCuomo@mintz.com.
`
`IV.
`
`37 C.F.R. § 42.8(b)(4) – SERVICE INFORMATION
`
`Please direct all correspondence to lead counsel and backup counsel at the
`
`contact information above. Patent Owner consents to service by electronic mail at
`
`all of the following email addresses:
`
`DGConlin@mintz.com
`KBCarr@mintz.com
`DCotta@mintz.com
`PJCuomo@mintz.com
`
`3
`
`
`
`Respectfully submitted,
`
`NISSAN CHEMICAL INDUSTRIES,
`LTD.,
`
`By its attorneys,
`
`/David G. Conlin/
`David G. Conlin, Reg. No. 27,026
`Kathleen B. Carr, Reg. No.41,658
`Mintz, Levin, Cohn, Ferris, Glovsky and
`Popeo, P.C.
`One Financial Center
`Boston, MA 02111
`617-542-6000
`617-542-2241 fax
`DGConlin@mintz.com
`KBCarr@mintz.com
`
`4
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a copy of the foregoing Patent
`
`Owner’s Mandatory Notice was served on August 20, 2015 by sending a copy by
`
`overnight courier and by email to:
`
`Kenneth J. Burchfiel
`Sughrue Mion, PLLC
`2100 Pennsylvania Ave., NW
`Washington, DC 20037
`Phone: 202-293-7060
`Fax: 202-293-7860
`kburchfiel@sughrue.com
`
`/David G. Conlin/
`David G. Conlin
`Reg. No. 27,026
`
`5